Benzinga | Mar 24, 2021 08:06AM EDT

Akebia Therapeutics Announces Approval For Additional Indication Of Riona For The Treatment Of Iron Deficiency Anemia In Adult Patients In Japan

Akebia Therapeutics, Inc. (NASDAQ:AKBA), today announced that its collaboration partner, Japan Tobacco Inc. (JT), received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) for an additional indication for Riona(r) Tablets 250mg (Riona) (generic name in Japan: ferric citrate hydrate) to treat adult patients with iron deficiency anemia (IDA) in Japan.